The short answer
Finerenone (Kerendia) is a nonsteroidal mineralocorticoid receptor antagonist (MRA) used to reduce the risk of kidney and cardiovascular complications in certain adults with type 2 diabetes and chronic kidney disease (CKD).
It is not simply a blood-pressure drug. Finerenone blocks the mineralocorticoid receptor, which can become overactive in diabetes and contribute to inflammation, fibrosis, albumin leakage, and kidney damage.
Large clinical trials have shown that finerenone can slow CKD progression and reduce cardiovascular events in appropriately selected people with type 2 diabetes and CKD. However, it is not a cure for diabetic kidney disease, and its most important safety issue is high blood potassium (hyperkalemia).
How finerenone helps the kidneys
The mineralocorticoid receptor responds mainly to hormones such as aldosterone, which help regulate sodium, potassium, and blood pressure.
In diabetes and CKD, excessive mineralocorticoid-receptor activity can contribute to processes that promote inflammation and scarring (fibrosis) in the kidneys and cardiovascular system.
Finerenone blocks this receptor. One measurable effect is a reduction in albuminuria, meaning less albumin leaking into the urine.
Importantly, lower albuminuria is not the only reason finerenone is used. Clinical trials have shown reductions in meaningful kidney and cardiovascular outcomes as well.
Who may benefit?
The strongest evidence is in adults with type 2 diabetes, CKD, and persistent albuminuria, particularly when albuminuria remains despite appropriate treatment with a renin-angiotensin system blocker such as an ACE inhibitor or ARB.
KDIGO recommends considering a nonsteroidal MRA such as finerenone in adults with type 2 diabetes, CKD, albuminuria above 30 mg/g, adequate kidney function, and normal potassium despite the maximum tolerated dose of a renin-angiotensin system inhibitor. It can also be used alongside an SGLT2 inhibitor when appropriate.
This does not mean everyone with diabetes or every person with CKD needs finerenone. The decision depends on kidney function, urine albumin, potassium, other medications, cardiovascular risk, and the overall treatment plan.
What did the major trials show?
In the FIDELIO-DKD trial, 5,734 people with type 2 diabetes and CKD were followed for a median of 2.6 years. The composite kidney outcome occurred in 17.8% of people receiving finerenone compared with 21.1% receiving placebo, corresponding to a hazard ratio of 0.82. Cardiovascular events were also reduced.
The FIGARO-DKD trial included 7,437 people with type 2 diabetes and CKD and focused primarily on cardiovascular outcomes. Finerenone reduced the composite cardiovascular outcome from 14.2% to 12.4%, with the difference driven mainly by fewer hospitalizations for heart failure.
These results support finerenone as a risk-reducing treatment, not a medication that reverses established kidney scarring.
Why potassium monitoring matters
Finerenone can increase blood potassium because mineralocorticoid receptors normally help the kidneys excrete potassium.
This is especially important in CKD because reduced kidney function itself can make potassium harder to eliminate.
Before starting treatment, clinicians generally check:
- Serum potassium
- eGFR, an estimate of kidney filtration
- Current medications and other factors that may raise potassium
Potassium and kidney function are then monitored during treatment. The FDA prescribing information says finerenone should not be started when serum potassium is above 5.0 mEq/L.
The goal is not to eliminate potassium-containing foods automatically. Dietary changes, if needed, should be based on the person’s actual potassium level, kidney function, medications, and clinical situation.
What about eGFR and creatinine?
Finerenone can cause changes in kidney measurements, so a change in creatinine after starting treatment should be interpreted in context rather than automatically labeled as kidney damage.
eGFR is an estimate of how well the kidneys are filtering blood. A single value is less informative than the trend:
Previous eGFR → current eGFR → size of change → time interval → clinical context
Hydration, recent illness, medications, blood-pressure changes, and other factors can also affect kidney-function measurements.
The FDA label recommends checking eGFR and potassium before treatment and using kidney function to determine the appropriate starting approach.
Finerenone vs spironolactone
Both drugs block the mineralocorticoid receptor, but they are not interchangeable in every situation.
Spironolactone is a steroidal MRA commonly used for conditions such as heart failure, resistant hypertension, and excess aldosterone.
Finerenone is a newer, nonsteroidal MRA with specific clinical-trial evidence for kidney and cardiovascular risk reduction in type 2 diabetes with CKD.
Finerenone was specifically studied in diabetic CKD populations, while the choice between different MRAs depends on the medical problem being treated. KDIGO notes that steroidal MRAs remain useful for conditions such as heart failure, hyperaldosteronism, and resistant hypertension.
What about type 1 diabetes?
The evidence is expanding.
A 2026 phase 3 trial in adults with type 1 diabetes, CKD, and albuminuria found that finerenone reduced urine albumin-to-creatinine ratio more than placebo over six months. However, this study primarily demonstrated an albuminuria benefit and was not designed to establish long-term kidney-failure or cardiovascular outcome benefits. Hyperkalemia was also more common with finerenone.
Therefore, evidence for finerenone in diabetic kidney disease should not be treated as identical for type 1 and type 2 diabetes.
What should you do if finerenone is prescribed?
Ask your clinician about:
- Your eGFR and potassium before starting
- Your urine albumin level
- Whether you are already receiving an ACE inhibitor or ARB and/or an SGLT2 inhibitor
- When potassium and kidney function should be rechecked
- Which other medicines or supplements could increase potassium
- What to do if you develop an illness causing significant dehydration or vomiting
Do not stop or change finerenone, an ACE inhibitor, ARB, SGLT2 inhibitor, or other prescribed medication on your own.
Bottom line
Finerenone is an evidence-based kidney and cardiovascular risk-reduction treatment for selected people with type 2 diabetes and CKD, particularly those with persistent albuminuria. Its benefits go beyond lowering urine albumin and include a lower risk of important kidney and cardiovascular outcomes.
The major safety issue is hyperkalemia, which is why potassium and kidney function need regular monitoring.
It should be viewed as one part of comprehensive diabetic kidney disease treatment—not as a cure and not as a replacement for blood-pressure control, diabetes management, ACE inhibitor/ARB therapy when indicated, SGLT2 inhibitors when appropriate, and individualized lifestyle and dietary care.